The Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) announced that they are working to stop misleading drug advertising. The first action taken to achieve this was a series of warning letters sent to pharmaceutical companies on September 9 by the FDA.
The FDA also reported that they sent around 100 cease-and-desist letters to organizations with ads considered misleading. The FDA will also require companies to list all safety risks associated with their drugs in advertisements. The agency emphasized in a press release that, “The FDA is concerned patients are not seeing a fair balance of information about drug products. This concern is magnified when serious risks are not clearly presented, or the information is too difficult for seniors to read or hear.”
Furthermore, the FDA plans to be stricter about drug advertising. Artificial intelligence (AI) and other tech are being used by the agency to investigate ads.
